Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Mutations in the RAS family of oncogenes are highly prevalent in human cancer and, amongst its manifold effects, oncogenic RAS impairs the expression of components of the antigen presentation pathway. This allows evasion of cytotoxic T lymphocytes (CTL). CTL and natural killer (NK) cells are reciprocally regulated by MHC class I molecules and any gain in CTL recognition obtained by therapeutic inactivation of oncogenic RAS may be offset by reduced NK cell activation. We have investigated the consequences of targeted inactivation of oncogenic RAS on the recognition by both CTL and NK cells. Inactivation of oncogenic RAS, either by genetic deletion or inactivation with an inducible intracellular domain antibody (iDAb), increased MHC class I expression in human colorectal cell lines. The common RAS mutations, at codons 12, 13 and 61, all inhibited antigen presentation. Although MHC class I modulates the activity of both CTL and NK cells, the enhanced MHC class I expression resulting from inactivation of mutant KRAS did not significantly affect the in vitro recognition of these cell lines by either class of cytotoxic lymphocyte. These results show that oncogenic RAS and its downstream signalling pathways modulate the antigen presentation pathway and that this inhibition is reversible. However, the magnitude of these effects was not sufficient to alter the in vitro recognition of tumour cell lines by either CTL or NK cells.

Original publication

DOI

10.1016/j.molimm.2013.11.020

Type

Journal article

Journal

Mol Immunol

Publication Date

04/2014

Volume

58

Pages

160 - 168

Keywords

Antigen presentation, MHC class I, Natural killer cells, RAS oncogene, Tumour immune evasion, Tumour immunology, Antibodies, Antigens, Surface, Cell Line, Tumor, Gene Deletion, HCT116 Cells, Histocompatibility Antigens Class I, Humans, Killer Cells, Natural, Lymphocyte Activation, Neoplasms, Proto-Oncogene Proteins, Proto-Oncogene Proteins p21(ras), T-Lymphocytes, Cytotoxic, ras Proteins